#China #Shanghai #Fosun Pharma #Gland Pharma #H-Share Buyback

Fosun Pharma Initiates H-Share Repurchase Plan

Shanghai Fosun Pharmaceutical (Group) Co., Ltd., commonly referred to as Fosun Pharma, has unveiled an ambitious H-share repurchase program. The company plans to buy back H-shares valued at up to HK$1 billion. This strategic move is intended to demonstrate strong management confidence in Fosun Pharma's inherent value and to reassure market stakeholders of the company's solid financial health.

The announcement, made on September 6, 2026, marks a significant step in Fosun Pharma's commitment to responsive market management. By implementing this share buyback, the firm aims not only to stabilize its stock prices but also to enhance shareholder returns by either canceling the repurchased shares or retaining them as treasury stock. This approach is part of Fosun's larger framework of sustaining long-term value for its stakeholders.

In the first half of 2026, Fosun Pharma reported a noticeable improvement in its earnings quality. The company achieved a revenue of RMB 20,442 million, which is a 4.75% increase compared to the same period the previous year. Profits attributable to shareholders rose significantly by 19.09% year-on-year, amounting to RMB 1,144 million after accounting for non-recurring gains and losses. Additionally, the firm generated a net cash flow from operating activities of approximately RMB 2,424 million, showcasing a revenue uplift of 13.59% over the same timeframe. These figures underline the robust operational performance and solid foundation upon which this buyback initiative is constructed.

Funding for this repurchase plan primarily derives from the disposal of about 6% equity interest in Gland Pharma, generating approximately US$294 million. Despite this sale, Fosun Pharma retains a significant stake in Gland Pharma, maintaining an approximate 45.76% equity interest. It is critical to note that Gland Pharma will continue to be included in Fosun Pharma's financial reports, ensuring integrated financial performance tracking.

The net proceeds from the Gland Pharma transaction will be strategically allocated towards research and development investments, facilitating further innovations and product developments. This reallocation signifies Fosun Pharma’s long-term vision for growth by fortifying its research capabilities while also addressing shareholder value through repurchases and debt repayments.

Looking to the future, Fosun Pharma remains steadfast in its commitment to innovation and global expansion. The company plans to accelerate progress in research and development, particularly focusing on its major pipeline candidates poised for commercialization. The introduction of this H-share repurchase program serves not just as a financial maneuver but as a testament to Fosun Pharma's confidence in its business model and value proposition.

In conclusion, Fosun Pharma's proactive approach indicates an unwavering confidence in its business health and commitment to maximizing shareholder value. As the pharmaceutical landscape continues to shift, this buyback initiative is a pivotal step towards ensuring that both investors and the market remain assured of Fosun Pharma's enduring success and stability in the industry.